<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20241119151218&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20241119151218&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 19 Nov 2024 20:12:19 +0000</lastbuilddate>
<pubDate>Tue, 19 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>STOPDAPT-3 one-year results support similar efficacy and safety of aspirin and clopidogrel after percutaneous coronary intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39560672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 19:ehae773. doi: 10.1093/eurheartj/ehae773. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39560672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39560672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae773>10.1093/eurheartj/ehae773</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39560672</guid>
<pubDate>Tue, 19 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-11-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>STOPDAPT-3 one-year results support similar efficacy and safety of aspirin and clopidogrel after percutaneous coronary intervention</dc:title>
<dc:identifier>pmid:39560672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae773</dc:identifier>
</item>
<item>
<title>Stroke risk in device-detected atrial fibrillation is modulated by the continuum of vascular disease burden</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39560670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 19:ehae797. doi: 10.1093/eurheartj/ehae797. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39560670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39560670</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae797>10.1093/eurheartj/ehae797</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39560670</guid>
<pubDate>Tue, 19 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dominik Linz</dc:creator>
<dc:creator>Sevasti-Maria Chaldoupi</dc:creator>
<dc:date>2024-11-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Stroke risk in device-detected atrial fibrillation is modulated by the continuum of vascular disease burden</dc:title>
<dc:identifier>pmid:39560670</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae797</dc:identifier>
</item>
<item>
<title>First past the post: research on endurance exercise wins the Desmond Julian Award</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39560667/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 19:ehae750. doi: 10.1093/eurheartj/ehae750. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39560667/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39560667</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae750>10.1093/eurheartj/ehae750</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39560667</guid>
<pubDate>Tue, 19 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-11-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>First past the post: research on endurance exercise wins the Desmond Julian Award</dc:title>
<dc:identifier>pmid:39560667</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae750</dc:identifier>
</item>
<item>
<title>Cholesterol crystals in the pathogenesis of atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39558130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>The presence of cholesterol crystals (CCs) in tissues was first described more than 100 years ago. CCs have a pathogenic role in various cardiovascular diseases, including myocardial infarction, aortic aneurysm and, most prominently, atherosclerosis. Although the underlying mechanisms and signalling pathways involved in CC formation are incompletely understood, numerous studies have highlighted the existence of CCs at various stages of atheroma progression. In this Review, we summarize the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 18. doi: 10.1038/s41569-024-01100-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The presence of cholesterol crystals (CCs) in tissues was first described more than 100 years ago. CCs have a pathogenic role in various cardiovascular diseases, including myocardial infarction, aortic aneurysm and, most prominently, atherosclerosis. Although the underlying mechanisms and signalling pathways involved in CC formation are incompletely understood, numerous studies have highlighted the existence of CCs at various stages of atheroma progression. In this Review, we summarize the mechanisms underlying CC formation and the role of CCs in cardiovascular disease. In particular, we explore the established links between lipid metabolism across various cell types and the formation of CCs, with a focus on CC occurrence in the vasculature. We also discuss CC-induced inflammation as one of the pathogenic features of CCs in the atheroma. Finally, we summarize the therapeutic strategies aimed at reducing CC-mediated atherosclerotic burden, including approaches to inhibit CC formation in the vasculature or to mitigate the inflammatory response triggered by CCs. Addressing CC formation might emerge as a crucial component in our broader efforts to combat cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39558130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39558130</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01100-3>10.1038/s41569-024-01100-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39558130</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yvonne Baumer</dc:creator>
<dc:creator>Jason Irei</dc:creator>
<dc:creator>William A Boisvert</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cholesterol crystals in the pathogenesis of atherosclerosis</dc:title>
<dc:identifier>pmid:39558130</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01100-3</dc:identifier>
</item>
<item>
<title>Semaglutide Eligibility Across All Current Indications for US Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 18. doi: 10.1001/jamacardio.2024.4657. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556764</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4657>10.1001/jamacardio.2024.4657</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556764</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ivy Shi</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:creator>Issa J Dahabreh</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Semaglutide Eligibility Across All Current Indications for US Adults</dc:title>
<dc:identifier>pmid:39556764</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4657</dc:identifier>
</item>
<item>
<title>Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance and well-being; and reduced symptoms and medication burden in patients with HFpEF and obesity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072679. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical endpoints, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden in these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: 731 patients in class II-IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m<sup>2</sup> were randomized(double-blind) to tirzepatide(titrated up to 15mg subcutaneously weekly)(n=364) or placebo(n=367), added to background therapy for a median of 104 weeks (Q1=66, Q3=126 weeks).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">PRIMARY ENDPOINTS: tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score(KCCQ-CSS). The current expanded analysis included sensitivity analyses of the primary endpoints, 6-minute walk distance(6MWD), EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health(PGIS), NYHA class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in KCCQ-CSS and 6MWD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patients were aged 65.2±10.7, 53.8%(n=393) were female; BMI 38.2±6.7kg/m<sup>2</sup>, KCCQ-CSS 53.5±18.5, 6MWD 302.8±81.7meters, and 53%(n=388) had a worsening heart failure event in the prior 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time-to-first-event (hazard ratios 0.41-0.67). At 52 weeks, tirzepatide increased KCCQ-CSS 6.9 points (95%CI, 3.3, 10.6, P&lt;0.001), 6MWD 18.3 meters (95%CI, 9.9, 26.7, P&lt;0.001) and EQ-5D-5L 0.06 (95%CI, 0.03, 0.09, P&lt;0.001). The tirzepatide group shifted to a more favorable PGIS (proportional odds ratio 1.99 (95%CI, 1.44, 2.76) and NYHA class (proportional odds ratio 2.26 (95%CI, 1.54, 3.31), both P&lt;0.001 and required less heart failure medications (P=0.015). The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio 1.63, 95%CI, 1.17, 2.28;P=0.004).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance and well-being; and reduced symptoms and medication burden in patients with HFpEF and obesity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556714</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072679>10.1161/CIRCULATIONAHA.124.072679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556714</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Christopher M Kramer</dc:creator>
<dc:creator>Seth J Baum</dc:creator>
<dc:creator>Sheldon E Litwin</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Yang Ou</dc:creator>
<dc:creator>Govinda J Weerakkody</dc:creator>
<dc:creator>Karla C Hurt</dc:creator>
<dc:creator>Chisom Kanu</dc:creator>
<dc:creator>Masahiro Murakami</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>SUMMIT Trial Study Group</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity</dc:title>
<dc:identifier>pmid:39556714</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072679</dc:identifier>
</item>
<item>
<title>Correction to: 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556658/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 19;150(21):e466. doi: 10.1161/CIR.0000000000001298. Epub 2024 Nov 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556658/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556658</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001298>10.1161/CIR.0000000000001298</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556658</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39556658</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001298</dc:identifier>
</item>
<item>
<title>Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 19;150(21):1669-1670. doi: 10.1161/CIRCULATIONAHA.124.071851. Epub 2024 Nov 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556657</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071851>10.1161/CIRCULATIONAHA.124.071851</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556657</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jonathan M Tobis</dc:creator>
<dc:creator>John D Carroll</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable?</dc:title>
<dc:identifier>pmid:39556657</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071851</dc:identifier>
</item>
<item>
<title>Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians. Arguably, cardiovascular prevention and population health are poised for innovation to guide evaluation and management, as these...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 19;150(21):1720-1731. doi: 10.1161/CIRCULATIONAHA.124.070081. Epub 2024 Nov 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians. Arguably, cardiovascular prevention and population health are poised for innovation to guide evaluation and management, as these areas are already informed by risk-assessment, but limited by the use of crude assessment tools with marginal performance. Risk assessment in prevention and population health may be improved with the use of genetics, circulating biomarkers, and imaging, leading to outcome-specific risk-prediction and enhanced phenotyping. Personalized management matching therapy to risk profile can be then implemented for either individuals or groups, improving cost-effectiveness and risk-benefit. Here, we explore this precision-like approach, including available tools, potential applications, and future perspectives for cardiovascular prevention and population health management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556656</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070081>10.1161/CIRCULATIONAHA.124.070081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556656</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Fernando R Giugni</dc:creator>
<dc:creator>Jarett D Berry</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?</dc:title>
<dc:identifier>pmid:39556656</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070081</dc:identifier>
</item>
<item>
<title>Screening for Cardiac Involvement in Carriers of Pathogenic &lt;em>;TTR&lt;/em>; Variants: Proposal for an Approach Based on High-Sensitivity Troponin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556655/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 19;150(21):1656-1658. doi: 10.1161/CIRCULATIONAHA.124.071253. Epub 2024 Nov 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556655/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556655</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071253>10.1161/CIRCULATIONAHA.124.071253</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556655</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Chiara Sanguinetti</dc:creator>
<dc:creator>Maria Franzini</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Screening for Cardiac Involvement in Carriers of Pathogenic &lt;em>;TTR&lt;/em>; Variants: Proposal for an Approach Based on High-Sensitivity Troponin</dc:title>
<dc:identifier>pmid:39556655</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071253</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556654/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 19;150(21):1732-1736. doi: 10.1161/CIRCULATIONAHA.124.072367. Epub 2024 Nov 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556654/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556654</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072367>10.1161/CIRCULATIONAHA.124.072367</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556654</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39556654</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072367</dc:identifier>
</item>
<item>
<title>Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556653/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 19;150(21):1653-1655. doi: 10.1161/CIRCULATIONAHA.124.070104. Epub 2024 Nov 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556653/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556653</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070104>10.1161/CIRCULATIONAHA.124.070104</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556653</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Vallerie V McLaughlin</dc:creator>
<dc:creator>Marc Humbert</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions</dc:title>
<dc:identifier>pmid:39556653</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070104</dc:identifier>
</item>
<item>
<title>Letter by Lucijanic and Krecak Regarding Article, "Clonal Hematopoiesis of Indeterminate Potential With Loss of &lt;em>;Tet2&lt;/em>; Enhances Risk for Atrial Fibrillation Through &lt;em>;Nlrp3&lt;/em>; Inflammasome Activation"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556652/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 19;150(21):e447-e448. doi: 10.1161/CIRCULATIONAHA.124.069352. Epub 2024 Nov 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556652/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556652</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069352>10.1161/CIRCULATIONAHA.124.069352</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556652</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marko Lucijanic</dc:creator>
<dc:creator>Ivan Krecak</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Lucijanic and Krecak Regarding Article, "Clonal Hematopoiesis of Indeterminate Potential With Loss of &lt;em>;Tet2&lt;/em>; Enhances Risk for Atrial Fibrillation Through &lt;em>;Nlrp3&lt;/em>; Inflammasome Activation"</dc:title>
<dc:identifier>pmid:39556652</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069352</dc:identifier>
</item>
<item>
<title>Low-Density Lipoprotein Cholesterol Level Distributions Across Different Ages: Implications for Screening Children for Severe and Familial Hypercholesterolemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 19;150(21):1741-1744. doi: 10.1161/CIRCULATIONAHA.124.069792. Epub 2024 Nov 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556651</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069792>10.1161/CIRCULATIONAHA.124.069792</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556651</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Junxiu Liu</dc:creator>
<dc:creator>Brandon K Bellows</dc:creator>
<dc:creator>David R Jacobs</dc:creator>
<dc:creator>Jessica G Woo</dc:creator>
<dc:creator>Elaine M Urbina</dc:creator>
<dc:creator>Pallavi P Balte</dc:creator>
<dc:creator>Elizabeth C Oelsner</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>David Siscovick</dc:creator>
<dc:creator>Norrina B Allen</dc:creator>
<dc:creator>Jamal S Rana</dc:creator>
<dc:creator>John T Wilkins</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Lydia A Bazzano</dc:creator>
<dc:creator>Trudy L Burns</dc:creator>
<dc:creator>Stephen R Daniels</dc:creator>
<dc:creator>Terence Dwyer</dc:creator>
<dc:creator>Markus Juonala</dc:creator>
<dc:creator>Olli T Raitakari</dc:creator>
<dc:creator>Alan R Sinaiko</dc:creator>
<dc:creator>Julia Steinberger</dc:creator>
<dc:creator>Alison J Venn</dc:creator>
<dc:creator>Noora Kartiosuo</dc:creator>
<dc:creator>Terho Lehtimäki</dc:creator>
<dc:creator>Costan G Magnussen</dc:creator>
<dc:creator>Jorma S A Viikari</dc:creator>
<dc:creator>Sarah D de Ferranti</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Low-Density Lipoprotein Cholesterol Level Distributions Across Different Ages: Implications for Screening Children for Severe and Familial Hypercholesterolemia</dc:title>
<dc:identifier>pmid:39556651</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069792</dc:identifier>
</item>
<item>
<title>Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: For patients with HF and an LVEF greater than 40%, discharge prescription of SGLT2is increased from 4.2% to 23.5% during the first 2 years after the EMPEROR-Preserved trial demonstrating treatment benefits; however, these rates varied across US hospitals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 18. doi: 10.1001/jamacardio.2024.4489. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%. Nationwide adoption of SGLT2is in the US since publication of the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) in August 2021 is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine trends and hospital-level variation in SGLT2i adoption.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients with LVEF greater than 40% who were hospitalized for decompensated HF at 1 of 557 sites in the US between July 1, 2021, and September 30, 2023, from the Get With The Guidelines-Heart Failure registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Patient-level trends and site-level variation in prescription rates of SGLT2i at hospital discharge. Site-level variation was quantified using the median odds ratio, which describes the average odds that a patient being treated at one vs another randomly selected hospital would receive SGLT2i therapy at discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 158 849 patients (median [IQR] age, 76 [66-85] years; 89 816 females [56.5%]), 22 126 eligible patients (13.9%) with HF and an LVEF greater than 40% were prescribed an SGLT2i at hospital discharge. Quarterly prescription rates increased from 4.2% in July to September 2021 to 23.5% in July to September 2023 (P for trend &lt; .001). SGLT2i prescription was more likely among patients with HF with mildly reduced LVEF (41%-49%) than in those with preserved LVEF (≥50%; 5127 of 27 712 patients [18.5%] vs 16 999 of 131 137 patients [13.0%]; absolute standardized difference, 16.7%). After adjustment for patient characteristics, there was a high variance between hospitals in the rate of SGLT2i prescription (median odds ratio, 2.12; 95% CI, 2.02-2.25). Among 518 hospitals with 10 or more eligible discharges, 11 hospitals (2.1%) discharged 50% or more of their patients with an SGLT2i prescription, while 232 (44.8%) discharged fewer than 10% of eligible patients with an SGLT2i prescription.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: For patients with HF and an LVEF greater than 40%, discharge prescription of SGLT2is increased from 4.2% to 23.5% during the first 2 years after the EMPEROR-Preserved trial demonstrating treatment benefits; however, these rates varied across US hospitals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556474</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4489>10.1001/jamacardio.2024.4489</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556474</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mohammad Abdel Jawad</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Uchechukwu Ikeaba</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Karen Chiswell</dc:creator>
<dc:creator>Paul S Chan</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39556474</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4489</dc:identifier>
</item>
<item>
<title>Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556242/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Early initiation and continuous use of acoramidis in the ATTRibute-CM study through M42 of the ongoing OLE study was associated with sustained clinical benefits in a contemporary ATTR-CM cohort, with no clinically important safety issues newly identified.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072771. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the phase 3 randomized controlled study, ATTRibute-CM, acoramidis, a transthyretin (TTR) stabilizer, demonstrated significant efficacy on the primary endpoint. Participants with transthyretin amyloid cardiomyopathy (ATTR-CM) who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants who previously received acoramidis through Month 30 (M30) in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through M30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through Month 42 (M42) included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP), 6-minute walk distance (6MWD), serum TTR, and the Kansas City Cardiomyopathy Questionnaire Overall Summary score (KCCQ-OS). Safety outcomes were analyzed through M42.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 438 of 632 participants in ATTRibute-CM completed treatment and 389 enrolled in the ongoing OLE (263 continuous acoramidis, 126 placebo to acoramidis). The hazard ratio (HR) (95% CI) for ACM or first CVH was 0.57 (0.46, 0.72) at M42 based on a stratified Cox proportional hazards model (<i>P</i>-value &lt; 0.0001) favoring continuous acoramidis. Similar analyses were performed on ACM alone and first CVH alone, with HRs (95% CI) of 0.64 (0.47, 0.88) and 0.53 (0.41, 0.69), respectively, at M42. Treatment effects for NT-proBNP and 6MWD also favored continuous acoramidis. Upon initiation of open-label acoramidis in the placebo-to-acoramidis arm there was a prompt increase in serum TTR. Quality of life assessed by KCCQ-OS was well preserved in continuous acoramidis participants compared with the placebo to acoramidis participants. No new clinically important safety issues were identified in this long-term evaluation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Early initiation and continuous use of acoramidis in the ATTRibute-CM study through M42 of the ongoing OLE study was associated with sustained clinical benefits in a contemporary ATTR-CM cohort, with no clinically important safety issues newly identified.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556242/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556242</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072771>10.1161/CIRCULATIONAHA.124.072771</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556242</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniel P Judge</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Kevin M Alexander</dc:creator>
<dc:creator>Amrut V Ambardekar</dc:creator>
<dc:creator>Francesco Cappelli</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:creator>Pablo García-Pavía</dc:creator>
<dc:creator>Justin L Grodin</dc:creator>
<dc:creator>Martha Grogan</dc:creator>
<dc:creator>Mazen Hanna</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Jose Nativi-Nicolau</dc:creator>
<dc:creator>Laura Obici</dc:creator>
<dc:creator>Steen Hvitfeldt Poulsen</dc:creator>
<dc:creator>Nitasha Sarswat</dc:creator>
<dc:creator>Keyur Shah</dc:creator>
<dc:creator>Prem Soman</dc:creator>
<dc:creator>Ted Lystig</dc:creator>
<dc:creator>Xiaofan Cao</dc:creator>
<dc:creator>Kevin Wang</dc:creator>
<dc:creator>Maria Lucia Pecoraro</dc:creator>
<dc:creator>Jean-François Tamby</dc:creator>
<dc:creator>Leonid Katz</dc:creator>
<dc:creator>Uma Sinha</dc:creator>
<dc:creator>Jonathan C Fox</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial</dc:title>
<dc:identifier>pmid:39556242</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072771</dc:identifier>
</item>
<item>
<title>Defibrillation and refractory ventricular fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 18:ehae767. doi: 10.1093/eurheartj/ehae767. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556204</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae767>10.1093/eurheartj/ehae767</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556204</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Bas J Verkaik</dc:creator>
<dc:creator>Robert G Walker</dc:creator>
<dc:creator>Tyson G Taylor</dc:creator>
<dc:creator>Mette M Ekkel</dc:creator>
<dc:creator>Rob Marx</dc:creator>
<dc:creator>Remy Stieglis</dc:creator>
<dc:creator>Vera G M van Eeden</dc:creator>
<dc:creator>Lotte C Doeleman</dc:creator>
<dc:creator>Michiel Hulleman</dc:creator>
<dc:creator>Fred W Chapman</dc:creator>
<dc:creator>Hans van Schuppen</dc:creator>
<dc:creator>Christian van der Werf</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Defibrillation and refractory ventricular fibrillation</dc:title>
<dc:identifier>pmid:39556204</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae767</dc:identifier>
</item>
<item>
<title>Correction to: Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 18:ehae818. doi: 10.1093/eurheartj/ehae818. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556197</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae818>10.1093/eurheartj/ehae818</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556197</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:date>2024-11-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score</dc:title>
<dc:identifier>pmid:39556197</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae818</dc:identifier>
</item>
<item>
<title>Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556124/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072445. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction &lt;50% (2 with left ventricular ejection fraction ≤30%; 1 death). Of these, 12 of 15 (80%) continued treatment. New-onset atrial fibrillation occurred in 11 (10.2%) patients (4.55 per 100 patient-years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556124/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556124</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072445>10.1161/CIRCULATIONAHA.124.072445</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556124</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Milind Y Desai</dc:creator>
<dc:creator>Kathy Wolski</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Jeffrey B Geske</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Mark Sherrid</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Albree Tower-Rader</dc:creator>
<dc:creator>David Fermin</dc:creator>
<dc:creator>Srihari S Naidu</dc:creator>
<dc:creator>Nicholas G Smedira</dc:creator>
<dc:creator>Hartzell Schaff</dc:creator>
<dc:creator>Zhiqun Gong</dc:creator>
<dc:creator>Lana Mudarris</dc:creator>
<dc:creator>Kathy Lampl</dc:creator>
<dc:creator>Amy J Sehnert</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:creator>VALOR-HCM investigators</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM</dc:title>
<dc:identifier>pmid:39556124</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072445</dc:identifier>
</item>
<item>
<title>Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, the 18-month rivaroxaban treatment was superior to the 6-month rivaroxaban treatment with respect to recurrent VTE events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072758. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 32 institutions in Japan, we randomly assigned patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, in a 1:1 ratio, to receive either an 18-month or a 6-month rivaroxaban treatment. The primary end point was recurrent venous thromboembolism (VTE) at 18 months. The major secondary end point was major bleeding at 18 months according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that an 18-month treatment was superior to a 6-month treatment in terms of the primary end point.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From February 2021 to March 2023, 179 patients were randomized, and after the exclusion of one patient who withdrew consent, 178 were included in the intention-to-treat population: 89 patients in the 18-month rivaroxaban group and 89 in the 6-month rivaroxaban group. The mean age was 65.7 years; 47% of the patients were men, and 12% had symptoms of PE at baseline. The primary end point of recurrent VTE occurred in 5 of the 89 patients (5.6%) in the 18-month rivaroxaban group and in 17 of the 89 (19.1%) in the 6-month rivaroxaban group (odds ratio, 0.25 [95% CI, 0.09-0.72]; <i>P</i>=0.01). Among 22 recurrent VTE, 5 patients presented with a symptomatic recurrent VTE; recurrent PE occurred in 11 patients, including 2 with main and 4 with lobar PEs; and recurrent deep vein thrombosis was seen in 11 patients, including 3 with proximal deep vein thromboses. The major secondary end point of major bleeding occurred in 7 of the 89 patients (7.8 %) in the 18-month rivaroxaban group and in 5 of the 89 patients (5.6%) in the 6-month rivaroxaban group (odds ratio, 1.43 [95% CI, 0.44-4.70]; <i>P</i>=0.55).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, the 18-month rivaroxaban treatment was superior to the 6-month rivaroxaban treatment with respect to recurrent VTE events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39556015</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072758>10.1161/CIRCULATIONAHA.124.072758</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556015</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yugo Yamashita</dc:creator>
<dc:creator>Takeshi Morimoto</dc:creator>
<dc:creator>Nao Muraoka</dc:creator>
<dc:creator>Wataru Shioyama</dc:creator>
<dc:creator>Ryuki Chatani</dc:creator>
<dc:creator>Tatsuhiro Shibata</dc:creator>
<dc:creator>Yuji Nishimoto</dc:creator>
<dc:creator>Yoshito Ogihara</dc:creator>
<dc:creator>Kosuke Doi</dc:creator>
<dc:creator>Maki Oi</dc:creator>
<dc:creator>Taro Shiga</dc:creator>
<dc:creator>Daisuke Sueta</dc:creator>
<dc:creator>Kitae Kim</dc:creator>
<dc:creator>Yasuhiro Tanabe</dc:creator>
<dc:creator>Norimichi Koitabashi</dc:creator>
<dc:creator>Takuma Takada</dc:creator>
<dc:creator>Satoshi Ikeda</dc:creator>
<dc:creator>Hitoshi Nakagawa</dc:creator>
<dc:creator>Kengo Tsukahara</dc:creator>
<dc:creator>Masaaki Shoji</dc:creator>
<dc:creator>Jiro Sakamoto</dc:creator>
<dc:creator>Shinji Hisatake</dc:creator>
<dc:creator>Yutaka Ogino</dc:creator>
<dc:creator>Masashi Fujita</dc:creator>
<dc:creator>Naohiko Nakanishi</dc:creator>
<dc:creator>Tomohiro Dohke</dc:creator>
<dc:creator>Seiichi Hiramori</dc:creator>
<dc:creator>Ryuzo Nawada</dc:creator>
<dc:creator>Kazuhisa Kaneda</dc:creator>
<dc:creator>Koh Ono</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>ONCO PE Trial Investigators</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)</dc:title>
<dc:identifier>pmid:39556015</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072758</dc:identifier>
</item>
<item>
<title>Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide to Oral and Intravenous Formulations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39555978/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241119151218&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072949. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39555978/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241119151218&v=2.18.0.post9+e462414">39555978</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072949>10.1161/CIRCULATIONAHA.124.072949</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39555978</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Andrew P Ambrosy</dc:creator>
<dc:creator>Daniel Bensimhon</dc:creator>
<dc:creator>Galina Bernstein</dc:creator>
<dc:creator>Brian Kolski</dc:creator>
<dc:creator>Joel Neutel</dc:creator>
<dc:creator>Benjamin Esque</dc:creator>
<dc:creator>Eric Adler</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide to Oral and Intravenous Formulations</dc:title>
<dc:identifier>pmid:39555978</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072949</dc:identifier>
</item>





























</channel>
</rss>